{"id":564339,"date":"2021-09-20T12:46:01","date_gmt":"2021-09-20T12:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564339"},"modified":"2021-09-20T12:46:01","modified_gmt":"2021-09-20T12:46:01","slug":"seborrhoeic-dermatitis-pipeline-report-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/seborrhoeic-dermatitis-pipeline-report-analysis-by-delveinsight_564339.html","title":{"rendered":"Seborrhoeic Dermatitis Pipeline Report Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1632120320.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Seborrhoeic Dermatitis Pipeline Report Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1632120320.png\" alt=\"Seborrhoeic Dermatitis Pipeline Report Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Seborrhoeic Dermatitis Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Currently, 5+ companies and 5+ pipeline drugs are in the Seborrhoeic Dermatitis pipeline landscape.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/e43c3ffd275705cda39c734c7e9f5762.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/seborrhoeic-dermatitis-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Seborrhoeic Dermatitis pipeline report<\/a><\/strong> provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Seborrhoeic Dermatitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">There are currently <strong>5+ drugs<\/strong> in the Seborrhoeic Dermatitis pipeline.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Seborrhoeic Dermatitis pipeline comprises therapies in different clinical phase stages, including <strong>ARQ-154, DBI-002, PAC 14028, MSB-7154,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Some of the companies actively working to improve the Seborrhoeic Dermatitis treatment landscape are <strong>Arcutis Biotherapeutics, Inc., DermBiont, Amorepacific, MatriSys Bio,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Seborrhoeic Dermatitis pipeline therapies that are in the late stage of development include <strong>ARQ-154 (Arcutis Biotherapeutics), DBI-002 (DermBiont), PAC 14028 (Amorepacific),<\/strong> along with others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>MSB-7154<\/strong> is being developed and investigated in the preclinical stage by <strong>MatriSys Bio.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a detailed analysis of the pipeline landscape @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/seborrhoeic-dermatitis-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Seborrhoeic Dermatitis Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Seborrhoeic Dermatitis, also known as seborrhoea, is a chronic skin condition. It is a skin condition distinguished by scaly patches and red skin, most notably on the scalp. Seborrhoea can also occur on oily body parts such as the face, sides of the nose, brows, ears, eyelids, upper chest, and back. Seborrhoeic dermatitis can cause stubborn dandruff in addition to scaly patches and red skin.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Seborrheic Dermatitis symptoms include:<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dandruff (skin flakes) on your scalp, hair, brows, beard, or mustache<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patches of greasy skin with flaky white or yellow scales or crust on the scalp, face, sides of the nose, brows, ears, eyelids, chest, armpits, groin area, or under the breasts.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Red skin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Itching<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The main options for Seborrheic Dermatitis treatments are medicated shampoos, creams, and lotions. Before turning to prescription medications, dermatologists advise patients to try home remedies first, such as over-the-counter dandruff shampoos.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Pipeline Analysis: Drug Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>ARQ-154: Arcutis Biotherapeutics, Inc.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">ARQ-154, or topical roflumilast foam, is a foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been licensed by the US Food and Drug Administration (FDA) for systemic use to lower the risk of COPD exacerbations since 2011.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase III<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT04973228:<\/strong> Arcutis Biotherapeutics, Inc. began a randomized, Phase III trial in July 2021 to assess the efficacy and safety of ARQ-154 Foam 0.3 percent Administered QD in subjects with Seborrheic Dermatitis.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">ARQ-154: Arcutis Biotherapeutics, Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DBI-002: DermBiont<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PAC 14028: Amorepacific<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MSB-7154: MatriSys Bio<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Find out the emerging therapies and companies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/seborrhoeic-dermatitis-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Seborrhoeic Dermatitis Treatment<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Product Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monotherapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Combination Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discovery<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-Clinical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase I<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase II<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase III<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-registration<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Route of Administration<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Molecule Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small Molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stem Cell Therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Targets<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immune System<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Kinase<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Mechanism of Action<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease Inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulatory<\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Key Players:<\/strong> Arcutis Biotherapeutics, Inc., DermBiont, Amorepacific, MatriSys Bio, among others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Seborrhoeic Dermatitis Pipeline Therapies:<\/strong> ARQ-154, DBI-002, PAC 14028, MSB-7154, and others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"81\" \/>\n<col width=\"543\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis- Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Preclinical Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis- Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis- Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis- Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Seborrhoeic Dermatitis Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Seborrhoeic Dermatitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">What treatments are available for seborrhoeic dermatitis?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many pharmaceutical companies are developing Seborrhoeic Dermatitis treatments?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Which of these firms&#8217; pharmaceuticals is the most widely used?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many Seborrhoeic Dermatitis medications is each company producing?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many drugs for Seborrheic Dermatitis are in the early, mid, or late stages of development?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many of the current therapies under development can be used alone or in combination with other treatments?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the essential industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices affecting seborrhoeic dermatitis?<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sebohrrea-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Sebohrrea Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Sebohrrea pipeline therapies and key companies, including <strong>Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=seborrhoeic-dermatitis-pipeline-report-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=seborrhoeic-dermatitis-pipeline-report-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seborrhoeic Dermatitis Pipeline Currently, 5+ companies and 5+ pipeline drugs are in the Seborrhoeic Dermatitis pipeline landscape. DelveInsight&rsquo;s Seborrhoeic Dermatitis pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/seborrhoeic-dermatitis-pipeline-report-analysis-by-delveinsight_564339.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-564339","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=564339"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/564339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=564339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=564339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=564339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}